Deliberate use of placebos in clinical practice: what we really know by Harris, Cory S & Raz, Amir
Deliberate use of placebos in
clinical practice: what we really
know
Cory S Harris,
1,2 Amir Raz
2,3
Increasingly a focus of research as well as media reports and online forums, the use of placebos in
clinical medicine extends beyond sugar pills and saline injections. Physician surveys conducted in
various countries invariably report that placebos are routinely used clinically, impure placebos more
frequently than the pure ones, and that physicians consider them to be of legitimate therapeutic
value. Inconsistent study methodologies and physician conceptualisations of placebos may
complicate the interpretation of survey data, but hardly negate the valuable insights these research
ﬁndings provide. Because impure placebos are often not recognised as such by practitioners, they
remain at the fringe of many placebo-related debates, hence quietly absent from discussions
concerning policy and regulation. The apparent popularity of impure placebos used in clinical
practice thus presents unresolved ethical concerns and should direct future discussion and
research.
Converging independently replicated
evidence suggests that physicians do use
placebos in clinical practice. Regardless of
deﬁnitions and conceptualisations, these
accounts suggest that, unlike most people,
many clinicians construe placebos as more
than inert ‘nothings’. The tendency to
equate placebos with nothing is rather
simplistic because it sweepingly dismisses
large bodies of research concerning active
placebos, impure placebos and what
placebos should or should not contain. The
ﬁeld of placebo science needs to unpack
a vast entanglement of parameters, incl-
uding psychosocial factors, such as expec-
tations, suggestions, symbolic thinking,
framing and cultural inﬂuences. This task
requires an appreciation of both the social
and life sciences,and a nuanced approach to
the use of placebos in the clinic.
Findings from recent surveys of health-
care professionals from several countries
propose that placebos are being used
clinically; however, conceptual and meth-
odological variations complicate the inter-
pretation of results and comparisons
between studies.
1 While media headlines
rarely tell the whole story, we should not
be too quick to dismiss what these studies
tell us about the use of placebos in clinical
care today. Conceptual differences on
placebo abound in the literature, notably,
inconsistent survey deﬁnitions and physi-
cian understandings of the terms ‘placebo’,
‘placebo response’, and ‘placebo effect’.
This potential confusion, however, is more
than an artefact; it reﬂects an ongoing
debate regarding the role of placebos in
clinical practice and research. Whereas to
some professionals the deﬁnition of
‘placebos as inert substances’ feels most
appropriate, broader conceptualisations are
widespread. For example, in surveys that
provided physicians with a choice of deﬁ-
nition for placebo, ‘an intervention that is
inert or innocuous’ was by far the least
popular answer.
23This trend may well
stem from, but certainly goes far beyond,
the tacit understanding of, and acquies-
cence to, placebos as zero. Physician
perceptions notwithstanding, prescribing
either inert or active interventions that are
patently unsubstantiated poses a serious
ethical conundrum.
According to systematic reviews, physi-
cians report using impure placebos more
frequently than pure placebos, with only
a small percentage turning to sugar pills or
saline injections.
14For example, only 20%
of physicians surveyed in Canada reported
using placebos, while fewer prescribed
inert substances, and many more used at
least one form of treatment ‘in situations
without demonstrated or expected clinical
efﬁcacy’.
2 Interestingly, US
3 and Danish
5
studies, respectively, report that 45% and
86% of physicians use placebos, but when
asked directly about treatment type,
physicians in both countries attest to using
pure and impure placebos in proportions
comparable with those described in the
Canadian study. Regardless of headlines,
which typically portray placebos as inac-
tive pills, overarching trends indicate that
clinicians more often dispense impure,
rather than pure, placebos.
PURITY MATTERS
The observation that physicians opt for
impure placebos rather than pure placebos
is disconcerting because most ethical
debates and professional policies focus
squarely on pure placebos. Clearly, delib-
erately prescribing inert tablets differs in
many ways from prescribing active treat-
ments, which may beneﬁt the patient
despite a lack of supporting evidence.
However, because physicians accept the
beneﬁt of placebo-like interventions,
267
these two examples share much in
common. Moreover, unless fully disclosed
to the patient, prescriptions for unproven
active interventions infringe on patient
autonomy and informed consent in the
same way that pure placebos do, yet the
active nature of these medicines also
carries the risk of adverse effects.
Whereas physician surveys identify
global patterns in the clinical use of
placebos, interpretation of regional differ-
encesdconceptually and practicallyd
must consider relevant sociocultural and
political environments. Despite the domi-
nance of modern biomedicine in all recently
surveyed countries, alternative medical
systems integrate alongside, or otherwise
coexist with, conventional medicine to
varying degrees. National healthcare
models also differ, for example, publicly
versus privately funded systems, as do legal
and regulatory frameworks, professional
codes and the social values in which they
evolved. Placebo effects vary as a function
of country and culture.
8 Perhaps such
cultural variations lend colour to physician
perceptions and the use of different types
of placebosdfor example, contributing to
the tendency of American physicians to
prescribe antibiotics as placebos, while
their colleagues in Canada and Denmark
tend to prescribe vitamins.
235
Qualitative methods, to complement
our quantitative approaches, are necessary
to better capture the nuanced views of
practicing physicians. And yet, we
continue to turn to quantitative studies in
order to identify new and pressing direc-
tions for future research. For example,
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CommentaryCanadian psychiatrists are six times more
likely than non-psychiatrist physicians to
prescribe sub-therapeutic doses of drugs to
patients. In light of the incremental dosing
practices associated with antidepressants,
and the continuing controversy over their
clinical efﬁcacy for mild-to-moderate
depression, our team interviewed psychia-
trists to explore notions of sub-therapeutic
doses and to shed light on their roledas
well as that of placebo effectsdin the
clinical treatment of depression. Brieﬂy,
none of the interviewed psychiatrists
equated sub-therapeutic doses with
placebos, but several acknowledged that
placebo effects likely contribute to posi-
tive patient responses following ingestion
of very low doses. Furthermore, physi-
cians appear to promote placebo effects
through their interactions with patients,
consciously crafting language around the
topic of dose to shape expectancies of both
improvement and adverse effects.
9
Whereas psychiatrists may shy away from
explicitly invoking placebo effects,
elements of placebo medicine retain an
essential place in modern psychiatry.
CONCLUSION
Physician surveys from Europe, North
America and the Middle East consistently
report the clinical use of placebosd
predominantly impure and active
placebos. Regardless of methodological
discrepancies, these studies underscore the
need to expand ethical debates on the
clinical use of placebos beyond inert
treatments. With conceptual inconsis-
tencies leaving many physicians unaware
of the fact that they prescribe impure
placebos,
291 0educating medical students
about the science of placebosda topic
rarely taughtdis a fundamental step
towards clarifying misconceptions,
aligning terminologies and making ethical
and judicious use of placebos in clinical
practice.
11 From the American Medical
Association’s restrictive position to the
German Medical Association’s permissive
stance, policies regulating the use of
placebos are nascent and controversial
when they are not entirely absent, as is the
case in Canada. This May, stakeholders
ranging from physicians and scholars to
policy makers and lawyers will convene in
Montreal to seek consensus and to forward
Canadian policy recommendations. Only
through such opportunities to share
knowledge and exchange perspectives can
we tackle the complex nature and far-
reaching implications of the use of
placebos in the clinic.
< Do media headlines oversimplify the
nature and prevalence of the use of
placebos in modern medicine? Without
question.
< Do existing survey data, with their
inclusion of both pure and impure
placebos, inﬂate the perceived use of
inert treatments? Most likely.
< Do methodological differences between
studies obscure direct comparison of
results? To some extent.
< Should we disregard the insights gained
from this research for these reasons?
Absolutely not.
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